Acquisition (Tables)

9 Months Ended

Sep. 30, 2015

Business Acquisition, Pro Forma Information [Table Text Block]

The following supplemental table presents unaudited consolidated pro forma financial information as if the Closing of the CSC Acquisition had occurred on January 1, 2014 (in thousands, except per share amounts):



	Nine Months Ended September 30, 2014
	(As Reported)			(Pro forma)
Revenues	$	12,662		$	13,373
Net loss	$	(43,776	)	$	(46,273	)
Net loss attributable to Caladrius Biosciences, Inc.	$	(43,261	)	$	(45,758	)
Net loss per share attributable to Caladrius Biosciences, Inc.	$	(1.37	)	$	(1.24	)

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
Total	$	33,491